Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Jul;42(7):1706-12.
doi: 10.1128/AAC.42.7.1706.

Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits

Affiliations
Comparative Study

Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits

C Ostergaard et al. Antimicrob Agents Chemother. 1998 Jul.

Abstract

Moxifloxacin is a new 8-methoxyquinolone with high activity against gram-positive bacteria, including penicillin-resistant pneumococci. In an experimental meningitis model, we studied the pharmacokinetics of moxifloxacin in infected and uninfected rabbits and evaluated the antibiotic efficacies of moxifloxacin, ceftriaxone, and vancomycin against a penicillin-resistant Streptococcus pneumoniae strain (penicillin, ceftriaxone, vancomycin, and moxifloxacin MICs were 1, 0.5, 0.5, and 0.125 microgram/ml, respectively). Moxifloxacin entered cerebrospinal fluid (CSF) readily, with peak values within 15 to 30 min after bolus intravenous infusion and with a mean percent penetration into normal and purulent CSF of approximately 50 and 80%, respectively. The bactericidal effect of moxifloxacin was concentration dependent, and regrowth was seen only when the concentration of moxifloxacin in CSF was below the minimal bactericidal concentration. All antibiotic-treated groups (moxifloxacin given in two doses of 40 mg/kg of body weight, moxifloxacin in two 20-mg/kg doses, ceftriaxone in one 125-mg/kg dose, and vancomycin in two 20-mg/kg doses) had significantly higher reductions in CSF bacterial concentration than the untreated group (P < 0.05). Moxifloxacin was as effective as vancomycin and ceftriaxone in reducing bacterial counts at all time points tested (3, 5, 10, and 24 h). Moreover, moxifloxacin given in two 40-mg/kg doses resulted in a significantly higher reduction in CSF bacterial concentration (in log10 CFU per milliliter) than vancomycin within 3 h after the start of antibiotic treatment (3.49 [2.94 to 4.78] versus 2.50 [0.30 to 3.05]; P < 0.05). These results indicate that moxifloxacin could be useful in the treatment of meningitis, including penicillin-resistant pneumococcal meningitis.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
In vitro time-kill curves with a penicillin-resistant S. pneumoniae strain. Antibiotic concentrations are shown as multiples of the MIC for the strain. The lower limit of detection of bacteria was 1.7 log10 CFU/ml.
FIG. 2
FIG. 2
Median concentrations of bacteria in CSF and mean concentrations of antibiotics in CSF after the start of antibiotic therapy for experimental meningitis caused by a penicillin-resistant S. pneumoniae strain. Antibiotics were given as intravenous bolus infusions. The following differences were significant (P < 0.05): two 40-mg/kg doses of moxifloxacin versus vancomycin at 3 h; two 40-mg/kg doses of moxifloxacin versus two 20-mg/kg doses of moxifloxacin at 3, 5, and 10 h; all antibiotic groups versus the untreated control group. The lower limit of detection of bacteria was 1.7 log10 CFU/ml.
FIG. 3
FIG. 3
Median concentration of bacteria and mean concentration of moxifloxacin in CSF in a model of experimental meningitis (n = 3) caused by a penicillin-susceptible S. pneumoniae strain. The lower limit of detection of bacteria was 1.7 log10 CFU/ml.

Similar articles

Cited by

References

    1. Bradley J S, Scheld W M. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis. 1997;24:S213–S221. - PubMed
    1. Cavet M E, West M, Simmons N L. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 1997;121:1567–1578. - PMC - PubMed
    1. Dacey R G, Sande M A. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother. 1974;6:437–441. - PMC - PubMed
    1. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy (Basel) 1996;42:410–425. - PubMed
    1. Decazes J M, Mohler J, Bure A, Vallois J M, Meulemans A, Modai J. Pharmacokinetics of fleroxacin and its metabolites in serum, cerebrospinal fluid, and brain of rabbits with and without experimental Escherichia coli meningitis. Rev Infect Dis. 1989;11:1208–1209.

Publication types

MeSH terms

LinkOut - more resources